Table 2 Changes in patient baseline characteristics at 1 month and 6 months after baricitinib or tofacitinib

DAS28-CRP

2.8 (2.0–3.3)

2.17 (1.62–3.09)

2.7 (1.9–3.8)

2.12 (1.50–2.90)

-0.01

0.99

-1.05

0.29

TJC

1.00 (0–2.00)

0.00 (0.00–2.00)

2.00 (0–3.8)

0.0 (0.00–2.0)

-1.33

0.18

-0.84

0.40

SJC

2.00 (0–3.00)

1.00 (0.00–2.00)

1.0 (0–3.00)

0.0 (0.0–2.0)

-0.73

0.46

-0.30

0.76

VAS

3.0 (2.0–3.0)

2.00 (1.00–3.00)

2.9 (2.0–4.0)

1.0 (1.00–2.0)

-1.56

0.12

-3.87

0.00

CRP (mg/L)

3.9 (1.2–11.6)

2.70 (0.95–13.05)

3.0 (1.0–10.0)

2.30 (0.7–8.6)

-1.18

0.24

-1.19

0.24

ESR (mm/h)

34.0 (23.0–47.0)

30.00 (17.50–45.50)

31.5 (21.3–50.8)

27.00 (17.50–40.50)

-0.27

0.79

-0.70

0.49

RF (IU/mL)

60.0 (27.2–105.5)

59.10 (28.25–106.95)

73.3 (35.8–132.6)

66.30 (44.65–117.95)

-0.98

0.33

-0.89

0.37

WBC (×10⁹/L)

7.1 (5.7–8.3)

6.6 (5.5–8.0)

6.9 (5.5–9.2)

6.6 (5.3–7.9)

-0.38

0.71

-0.60

0.55

HGB (g/L)

118.8 (106.1–124.0)

116.5 ± 12.7

120.1 (109.1–129.8)

122.3 ± 14.6

-1.46

0.15

-2.32

0.02

PLT (×10⁹/L)

308.0 (267.0–359.0)

331.0(268.7–379.0)

276.0 (229.0–328.5)

264.0 (222.0–331.0)

-2.57

0.01

-3.44

0.001

NEU (×10⁹/L)

4.2 (3.2–5.4)

4.1 (3.2–5.5)

4.4 (3.4–6.2)

4.1 (3.2–5.3)

-1.00

0.31

-0.58

0.56

LYM (×10⁹/L)

1.8 (1.6–2.5)

1.7 (1.3–2.0)

1.6 (1.3–2.2)

1.6 (1.3–2.0)

-1.73

0.08

-0.66

0.51